Transactions

Asset Sales

Hikma Pharmaceuticals

Sale of ANDAs

February 2016

North America

Teva

Sale of 22 generic products to ANI Pharmaceuticals

$25 million

July 2015

North America

ProSolus

Sale to Mission Pharmacal

June 2015

North America

Sandoz

Sale of ZONALON to Prestium Pharma

March 2015

North America

Phenex

Sale of Development Program for Non-Alcoholic Steatohepatitis and Other Liver Diseases to Gilead

Up to $470m

January 2015

North America

Flamel Technologies

Sale of Pessac plant to Recipharm AB

Up to €22 million

November 2014

North America

Sandoz

Divestiture of certain ANDAs to IDT Australia

Up to $18 million

October 2014

North America

Heritage Pharma

Divestiture of certain ANDAs to Epic Pharma

October 2014

North America

Concordia Healthcare

Acquisition of Donnatal from Revive Pharmaceuticals

$329 million

March 2014

North America

Zila

Sale of substantially all assets to DenMat

February 2014

North America

Teva

Sale of 31 ANDAs to ANI Pharmaceuticals

$12.5mm + Profit Share

December 2013

Asia, Africa, MidEast, Latin America

Shionogi

Sale of Naprelan to Alvogen

November 2013

Japan

Shionogi

Divestiture of Three Pediatric Drugs to Concordia Pharmaceuticals

May 2013

Japan

GTx

Sale of Fareston to Prostrakan / Kyowa Hakko Kirin

October 2012

North America

Shionogi

Divestiture of Cuvposa to Merz

August 2012

Japan

Xanodyne

Sale of Roxicodone to Covidien

August 2012

North America

Xanodyne

Sale of Rights to Amicar to Versapharm

August 2012

North America

Xanodyne

Sale of Zipsor to Depomed

August 2012

North America

Mission Pharmacal

Purchase of rights to Eletone for dermatologic applications

February 2012

North America

Xanodyne

Sale of prenatal vitamin franchise

October 2011

North America

Shionogi

Divestiture of Three Pediatric Drugs to Concordia Pharmaceuticals

Concordia Pharmaceuticals Inc. acquired the rights to three Shionogi Inc. products: Kapvay™, Orapred ODT®, and Orapred® OS. As part of the agreement Shionogi will provide transition services to Concordia. This divestiture allowed Shionogi put more focus and resources on those products that are strategically core to its operations, and to progress development of products in its pipeline. Shionogi Inc. is the U.S.-based subsidiary of Shionogi & Co., Ltd., headquartered in Osaka, Japan. Shionogi is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi Inc. is focused primarily on two therapeutic areas in the U.S.: women’s health and pain. In addition, Shionogi is engaged in new research in areas such as allergy and cancer.

Press Release

GTx

Sale of Fareston to Prostrakan / Kyowa Hakko Kirin

GTx sold the rights to Fareston, a metastatic breat cancer product, to ProStrakan Group plc (ProStrakan) for total cash consideration of $21.7 million. Fareston is a selective estrogen receptor modulator approved in the United States for the treatment of breast cancer in postmenopausal women. After deducting cash expenses relating to the transaction, GTx will receive net cash proceeds from the sale of approximately $19 million. ProStrakan, which is a subsidiary of the pharmaceutical company, Kyowa Hakko Kirin Co. Ltd., executed an Asset Purchase Agreement with GTx to acquire GTx’s exclusive rights in the U.S. to Fareston, along with product inventory. This deal will allow GTx to focus its R&D capabilities to discover, develop, and commercialize other small molecule treatments. Special focus was placed on the development of Enobosarm, a molecule for the prevention and treatment of muscle wasting in patients who have non-small cell lung cancer, and on Capesaris, a molecule for men with advanced prostate cancer.

Press Release

Shionogi

Divestiture of Cuvposa to Merz

Shionogi Inc. sold its orphan product Cuvposa to Merz Pharmaceuticals LLC, the US division of private Germany drug company Merz GMBH & Co. Cuvposa is an oral solution medication designed to treat a condition associated with such neurologic conditions as cerebral palsy. The drug has been commercially available since April 2011 and is the only Food and Drug Administration-approved treatment to reduce chronic severe drooling — a condition known as sialorrhea — in pediatric patients ages 3 to 16 years with neurologic conditions associated with problem drooling. The acquisition of this drug is a promising addition to Merz’s neurology business and reflects its commitment to becoming a recognized leader in the treatment of movement disorders and related conditions in the U.S.

Press Release

Xanodyne

Sale of Roxicodone to Covidien

Xanodyne Pharmaceuticals, the developer of Roxicodone, sold the rights to Roxicodone to Covidien. Roxicodone is approved for moderate to severe pain management and is used where the application of an opioid analgesic is necessary. The drug is currently available in the U.S. As part of the deal, Covidine acquired the rights to Roxicodone (oxycodone hydrochloride tablets USP) in 5, 15 and 30 mg dosage strengths. The deal also gave Covidien all rights to the Roxicodone New Drug Application. The inclusion of Roxicodone enhances Covidine’s pain management product portfolio. Covidine’s pharmaceutical segment Mallinckrodt is a leading manufacturer of bulk acetaminophen in the world and the largest supplier of opioid pain management drugs in the U.S. Xanodyne Pharmaceuticals, an integrated specialty pharmaceutical company, has extensive expertise in pain management.

Xanodyne

Sale of Zipsor to Depomed

Xanodyne Pharmaceuticals sold all rights Zipsor to Depomed. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. The drug was introduced by Xanodyne in 2009, achieved approximately $19 million of net sales in the 12 months ended May 31, 2012. Depomed acquired the product in return for $25.9 million of cash and potential milestone payments based on sales of Zipsor and assumption of certain liabilities. With Depomed's extensive sales force of 164 reps and 78 flex reps, the company believes that Zipsor will achieve significant returns. The company plans to utilize its sales force to promote Zipsor to pain specialists, neurologists, and high prescribing PCPs, in addition to current prescribers of Zipsor.

Press Release

Mission Pharmacal

Purchase of rights to Eletone for dermatologic applications

Mission Pharmacal acquired the prescription barrier cream Eletone Cream, from Ferndale Healthcare, Inc. Eletone Cream is a non-steroidal, barrier cream approved by the FDA for the long-term treatment of atopic dermatitis, an inflammatory, chronically relapsing, non-contagious and pruritic or itchy skin disorder. The product enhances Mission's targeted expansion in the dermatology market. To augment and support its sales efforts, Mission has also created a dermatology focused sales team. Mission Pharmacal is a privately-held pharmaceutical company based in San Antonio, Texas. For more than 65 years, the company has been committed to meeting the unique healthcare needs of women throughout all stages of life, pediatric patients, and those persons dealing with urologic and dermatologic conditions.

Press Release